Status:
RECRUITING
Comparison Between the Efficacy of Residential and Ambulatory Weight Loss Programs for Pediatric Non-alcoholic Fatty Liver Disease
Lead Sponsor:
University Hospital, Ghent
Conditions:
Pediatric Non-alcoholic Fatty Liver Disease
Eligibility:
All Genders
8-18 years
Brief Summary
Non-alcoholic fatty liver disease (NAFLD) has become the most prevalent chronic liver disease worldwide, paralleling the obesity pandemic. Secondary to increasing rates of obesity in children and adol...
Eligibility Criteria
Inclusion
- Enrolled in the lifestyle management program for obesity in one of the participating centres
Exclusion
- Syndromic obesity
- Evidence of liver disease of other causes (viral, auto-immune, genetic)
- Average daily alcohol consumption of \>20g/day
- Unvalid screening Fibroscan
- Treatment with drugs which can induce liver steatosis or fibrosis (e.g. systemic corticosteroids, methotrexate)
Key Trial Info
Start Date :
May 1 2022
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 31 2031
Estimated Enrollment :
850 Patients enrolled
Trial Details
Trial ID
NCT05309863
Start Date
May 1 2022
End Date
December 31 2031
Last Update
June 4 2024
Active Locations (3)
Enter a location and click search to find clinical trials sorted by distance.
1
AZ Jan Palfijn
Ghent, East-Flanders, Belgium, 9000
2
University Hospital Gent
Ghent, East-Flanders, Belgium, 9000
3
Zeepreventorium
De Haan, West-Flanders, Belgium, 8420